



cket No. MPI00-336P1RM (previously 10448-081001)

Practitioner's
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Curtis, Rory A.J.
Application No.: 09/934,323 Group No.: 1652
Filed: August 21, 2001 Examiner: Nashed, Nashaat T.
For: 33410, A NOVEL HUMAN CARBOXYLESTERASE AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement submitted herewith is being filed:
 Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

- After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- with sufficient postage as first class mail. as "Express Mail Post Office to Address"
Mailing Label No. _____

TRANSMISSION

- transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: January 16, 2003

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-336P1RM (previously 10448-081001)

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

2. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE


3. Attached is a check in the amount of \$ _____.
 Charge Account No. 501668 in the amount of \$0.00.
 A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

January 16, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By *Marjo Cloutier*
Marjo Cloutier
Limited Recognition Under 37 C.F.R. §10.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820



Practitioner's Docket No. MPI00-336P1RM (previously 10448-081001)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Curtis, Rory A.J.
Application No.: 09/934,323 Group No.: 1652
Filed: August 21, 2001 Examiner: Nashed, Nashaat T.
For: 33410, A NOVEL HUMAN CARBOXYLESTERASE AND USES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements;
2. Forms PTO/SB/08A (substitute for Form PTO-1449);
3. Copy of Listed Information Item Accompanying This Statement (BB)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

- with sufficient postage as first class mail.

37 C.F.R. SECTION 1.10*

- as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

- transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: January 16, 2004

Sean Hunziker
(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copy of item listed in Form PTO/SB/08A (substitute for Form PTO-1449) accompanies this information statement.

January 16, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By: *Mario Cloutier*
Mario Cloutier
Limited Recognition Under 37 C.F.R. §10.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitut for form 1449A/PTO		<i>Complete if Known</i>	
		Application Number	09/934,323
		Filing Dat	August 21, 2001
		First Named Inventor	Curtis, Rory A.J.
		Group Art Unit	1652
		Examiner Name	Nashed, Nashaat T.
(use as many sheets as necessary)			
Sheet	1	of	1
		Attorney Docket Number	MPI00-336P1RM

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴ (if known)	Kind Code ⁵			
	BB		WO 01/27277	A2	Curagen Corporation	04-19-2001	Entire document

Examiner Signature		Date Considered	

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design numb r. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued th docum nt, by th two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, th indication of the year of the reign of the Emperor must precede th serial number of th patent document. ⁵Kind of document by th appropriate symbols as indicat d on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English languaq Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450